Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Alpha Cognition Inc

Healthcare US ACOG

6.08USD
-0.1(1.62%)

Last update at 2026-06-03T20:00:00Z

Day Range

6.056.29
LowHigh

52 Week Range

4.5011.54
LowHigh

Fundamentals

  • Previous Close 6.18
  • Market Cap150.02M
  • Volume5447
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-22.60212M
  • Revenue TTM10.22M
  • Revenue Per Share TTM0.58
  • Gross Profit TTM 8.30M
  • Diluted EPS TTM-1.18

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -20.66988M -14.63687M -13.77257M -12.11470M -19.54502M
Minority interest - - - - -
Net income -20.66988M -14.63687M -13.77257M -12.11470M -19.54502M
Selling general administrative 27.23M 7.22M 4.67M 4.02M 3.28M
Selling and marketing expenses 1.81M 0.10M 0.02M 0.03M 0.10M
Gross profit 8.30M -0.08122M - - -
Reconciled depreciation 0.06M 0.08M 0.08M 0.09M 0.09M
Ebit -22.71926M -14.45109M -13.70486M -11.94182M -19.01686M
Ebitda -22.66069M -14.36987M -13.62038M -11.85089M -18.92698M
Depreciation and amortization 0.06M 0.08M 0.08M 0.09M 0.09M
Non operating income net other - - - - -
Operating income -22.66069M -11.86065M -9.61781M -13.46562M -11.56873M
Other operating expenses 32.88M 11.86M 9.62M 13.47M 11.57M
Interest expense - 0.19M 0.07M 0.17M 0.53M
Tax provision - - - - -
Interest income 1.90M 0.16M 0.00680M 0.00193M 0.00207M
Net interest income 1.90M -0.48347M -0.06091M -0.17095M -0.52609M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue 10.22M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 30.97M 11.86M 9.62M 13.47M 11.57M
Cost of revenue 1.92M 0.08M - - -
Total other income expense net 1.99M -2.77621M -4.15475M 1.35M -7.97629M
Discontinued operations - - - - -
Net income from continuing ops -20.66988M -14.63687M -13.77257M -12.11470M -19.54502M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 79.73M 50.74M 2.45M 2.95M 12.88M
Intangible assets 0.39M 0.41M 0.53M 0.61M 0.70M
Earning assets - - - - -
Other current assets 3.55M 0.84M 0.37M 0.25M 0.87M
Total liab 17.20M 9.27M 7.16M 4.27M 3.85M
Total stockholder equity 62.53M 41.46M -4.71260M -1.32018M 9.03M
Deferred long term liab - - - - -
Other current liab - 1.57M 1.39M 0.83M 0.27M
Common stock 133.89M 99.13M 50.35M 40.26M 40.01M
Capital stock 133.89M 99.13M 50.35M 40.26M 40.01M
Retained earnings -97.10677M -76.28504M -63.35377M -49.98685M -38.03390M
Other liab - - - - -
Good will 0.39M - - - -
Other assets - - - - -
Cash 66.11M 48.55M 1.49M 2.08M 11.30M
Cash and equivalents - - - - -
Total current liabilities 9.13M 3.35M 2.62M 4.06M 1.80M
Current deferred revenue 0.15M - 0.01M - -
Net debt -66.10519M -47.63475M -0.27420M -0.87223M -10.22597M
Short term debt - 0.91M 1.22M 1.21M 1.08M
Short long term debt - 0.91M 1.22M 1.21M 1.08M
Short long term debt total - 0.91M 1.22M 1.21M 1.08M
Other stockholder equity 25.85M 18.72M - -0.00006M -
Property plant equipment - - - - -
Total current assets 79.01M 50.25M 1.92M 2.33M 12.17M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables 4.24M 0.25M 0.06M - -
Long term debt - - - - -
Inventory 5.12M 0.62M 0.00000M - -
Accounts payable 8.98M 0.87M 0.48M 2.02M 0.45M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.10430M -0.10430M 8.29M 8.41M 7.05M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.05M - - -
Deferred long term asset charges - - - - -
Non current assets total 0.72M 0.49M 0.53M 0.62M 0.71M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.02670M 0.00000M -0.00488M 0.46M
Change to liabilities - - - - -
Total cashflows from investing activities -0.29349M -0.02670M - -0.00488M 0.46M
Net borrowings -0.91146M 4.25M -0.05500M 0.00000M 0.00000M
Total cash from financing activities 38.21M 54.85M 8.16M 0.02M 14.88M
Change to operating activities - - - - -
Net income -20.66988M -14.63687M -13.77257M -12.11470M -19.54502M
Change in cash 17.54M 47.07M -0.58912M -9.21810M 5.38M
Begin period cash flow 48.56M 1.49M 2.08M 11.30M 5.93M
End period cash flow 66.11M 48.56M 1.49M 2.08M 11.30M
Total cash from operating activities -20.38037M -7.75565M -8.72879M -9.24165M -9.87934M
Issuance of capital stock 34.32M 56.54M 9.22M 0.00000M 13.65M
Depreciation 0.06M 0.08M 0.08M 0.09M 0.09M
Other cashflows from investing activities -0.29349M - - - -0.05000M
Dividends paid - - 0.00000M 0.00000M 0.00000M
Change to inventory -4.50836M -0.61513M 0.00000M - -
Change to account receivables -4.23614M 0.00000M - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities 0.04M -5.93452M -1.00935M 0.02M 1.23M
Change to netincome - - - - -
Capital expenditures 0.29M 0.03M 0.00001M 0.00488M 0.06M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -4.61888M -0.24168M -1.55753M 2.73M -0.28896M
Stock based compensation 4.92M 0.98M 2.37M 1.70M 1.79M
Other non cash items -0.07271M 6.06M 4.15M -1.64977M 8.07M
Free cash flow -20.67386M -7.78235M -8.72879M -9.24653M -9.94300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ACOG
Alpha Cognition Inc		 -0.1 1.62% 6.08 - 26.88 14.68 2.39 9.98 -1.5718
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Alpha Cognition Inc

750 West Pender Street, Vancouver, BC, Canada, V6C 2T8

Key Executives

Name Title Year Born
Mr. Michael E. McFadden B.B.A. CEO & Director 1967
Ms. Lauren D'Angelo M.B.A. Chief Operating Officer 1978
Mr. Kenneth Anthony Cawkell B.A., LL.B. Founder, Consultant, Corporate Secretary & Director 1951
Mr. Henry Du CPA VP of Finance & Accounting and Interim CFO 1979
Dr. Denis G. Kay M.Sc., Ph.D. Chief Scientific Officer 1957
Mr. Timothy Ayers Head of Compliance NA
Ms. Amy Kincaid Executive Director, Head of Marketing & Commercial Strategy NA
Mr. Jack Kelly Executive Director & Head of Market Access NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.